Visit https://www.peervoice.com/GFE860 to view the entire programme with slides. After completing “Geoffrey Liu, MD, MSc, FRCPC, FISPE - Optimizing the Potential for Patients With ALK-Positive mNSCLC Throughout Their Treatment Journey”, participants will be able to: Discuss the importance of first-line treatment and the factors to consider when selecting a treatment strategy for patients with ALK-positive metastatic non–small-cell lung cancer (mNSCLC); Describe the evolving clinical evidence and guideline recommendations for the treatment of ALK-positive mNSCLC; Review the toxicities of the new generation tyrosine kinase inhibitors (TKIs) used as first-line in the treatment of ALK-positive mNSCLC; and Apply key learnings and strategies to enhance the toxicity management of new generation TKIs for optimal patient outcomes.